铂类药物晚期乳腺癌应用专家共识(2020版)

2021-02-28 中国医师协会肿瘤医师分会 中国综合临床.2021.27(2):97-105.

乳腺癌是全球范围内女性最常见、致死人数最多的恶性肿瘤,社会负担巨大。目前,化疗仍是晚期乳腺癌最重要的治疗方式之一,其中铂类药物是乳腺癌化疗的常用药物。中国医师协会肿瘤医师分会乳腺癌学组组织相关专家,基

中文标题:

铂类药物晚期乳腺癌应用专家共识(2020版)

发布日期:

2021-02-28

简要介绍:

乳腺癌是全球范围内女性最常见、致死人数最多的恶性肿瘤,社会负担巨大。目前,化疗仍是晚期乳腺癌最重要的治疗方式之一,其中铂类药物是乳腺癌化疗的常用药物。中国医师协会肿瘤医师分会乳腺癌学组组织相关专家,基于循证医学证据,深入探讨晚期乳腺癌中铂类药物的临床应用,针对其临床适宜阶段、方案、疗效、不良反应提出合理建议,以指导临床医师合理用药,进一步规范诊疗行为。

相关资料下载:
[AttachmentFileName(sort=1, fileName=铂类药物晚期乳腺癌应用专家共识(2020版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=569d21c0020838a0, title=铂类药物晚期乳腺癌应用专家共识(2020版), enTitle=, guiderFrom=中国综合临床.2021.27(2):97-105., authorId=0, author=, summary=乳腺癌是全球范围内女性最常见、致死人数最多的恶性肿瘤,社会负担巨大。目前,化疗仍是晚期乳腺癌最重要的治疗方式之一,其中铂类药物是乳腺癌化疗的常用药物。中国医师协会肿瘤医师分会乳腺癌学组组织相关专家,基, cover=https://img.medsci.cn/2021420/1618929972290_2020535.jpg, journalId=0, articlesId=null, associationId=896, associationName=中国医师协会肿瘤医师分会, associationIntro=null, copyright=0, guiderPublishedTime=Sun Feb 28 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>乳腺癌是全球范围内女性最常见、致死人数最多的恶性肿瘤,社会负担巨大。目前,化疗仍是晚期乳腺癌最重要的治疗方式之一,其中铂类药物是乳腺癌化疗的常用药物。中国医师协会肿瘤医师分会乳腺癌学组组织相关专家,基于循证医学证据,深入探讨晚期乳腺癌中铂类药物的临床应用,针对其临床适宜阶段、方案、疗效、不良反应提出合理建议,以指导临床医师合理用药,进一步规范诊疗行为。</p> </div> </div> </div>, tagList=[TagDto(tagId=285, tagName=乳腺癌), TagDto(tagId=40523, tagName=铂类药物)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=285, guiderKeyword=乳腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=21887, appHits=144, showAppHits=0, pcHits=683, showPcHits=21743, likes=4, shares=8, comments=12, approvalStatus=1, publishedTime=Tue Apr 20 23:14:38 CST 2021, publishedTimeString=2021-02-28, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Apr 20 22:46:19 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sun Dec 31 18:36:17 CST 2023, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=铂类药物晚期乳腺癌应用专家共识(2020版).pdf)])
铂类药物晚期乳腺癌应用专家共识(2020版).pdf
下载请点击:
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1184983, encodeId=d554118498350, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de232193495, createdName=1209b8a9m19暂无昵称, createdTime=Sun Jan 16 22:42:39 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076618, encodeId=9bc810e66182a, content=6666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5156162478, createdName=ms3000000333745611, createdTime=Fri Dec 03 18:32:05 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966533, encodeId=c697966533b1, content=先评论再获取,不留空不留白, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75bd5503572, createdName=ms9000001418724535, createdTime=Tue May 18 11:52:24 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075043, encodeId=fe3f10e50438b, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb965634387, createdName=ms8000001030180834, createdTime=Mon Nov 29 12:29:46 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075042, encodeId=76ac10e50420f, content=666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb965634387, createdName=ms8000001030180834, createdTime=Mon Nov 29 12:29:35 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
    2022-01-16 1209b8a9m19暂无昵称

    太棒了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1184983, encodeId=d554118498350, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de232193495, createdName=1209b8a9m19暂无昵称, createdTime=Sun Jan 16 22:42:39 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076618, encodeId=9bc810e66182a, content=6666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5156162478, createdName=ms3000000333745611, createdTime=Fri Dec 03 18:32:05 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966533, encodeId=c697966533b1, content=先评论再获取,不留空不留白, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75bd5503572, createdName=ms9000001418724535, createdTime=Tue May 18 11:52:24 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075043, encodeId=fe3f10e50438b, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb965634387, createdName=ms8000001030180834, createdTime=Mon Nov 29 12:29:46 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075042, encodeId=76ac10e50420f, content=666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb965634387, createdName=ms8000001030180834, createdTime=Mon Nov 29 12:29:35 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
    2021-12-03 ms3000000333745611

    6666

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1184983, encodeId=d554118498350, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de232193495, createdName=1209b8a9m19暂无昵称, createdTime=Sun Jan 16 22:42:39 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076618, encodeId=9bc810e66182a, content=6666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5156162478, createdName=ms3000000333745611, createdTime=Fri Dec 03 18:32:05 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966533, encodeId=c697966533b1, content=先评论再获取,不留空不留白, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75bd5503572, createdName=ms9000001418724535, createdTime=Tue May 18 11:52:24 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075043, encodeId=fe3f10e50438b, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb965634387, createdName=ms8000001030180834, createdTime=Mon Nov 29 12:29:46 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075042, encodeId=76ac10e50420f, content=666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb965634387, createdName=ms8000001030180834, createdTime=Mon Nov 29 12:29:35 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
    2021-05-18 ms9000001418724535

    先评论再获取,不留空不留白

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1184983, encodeId=d554118498350, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de232193495, createdName=1209b8a9m19暂无昵称, createdTime=Sun Jan 16 22:42:39 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076618, encodeId=9bc810e66182a, content=6666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5156162478, createdName=ms3000000333745611, createdTime=Fri Dec 03 18:32:05 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966533, encodeId=c697966533b1, content=先评论再获取,不留空不留白, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75bd5503572, createdName=ms9000001418724535, createdTime=Tue May 18 11:52:24 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075043, encodeId=fe3f10e50438b, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb965634387, createdName=ms8000001030180834, createdTime=Mon Nov 29 12:29:46 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075042, encodeId=76ac10e50420f, content=666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb965634387, createdName=ms8000001030180834, createdTime=Mon Nov 29 12:29:35 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
    2021-11-29 ms8000001030180834

    太棒了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1184983, encodeId=d554118498350, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de232193495, createdName=1209b8a9m19暂无昵称, createdTime=Sun Jan 16 22:42:39 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076618, encodeId=9bc810e66182a, content=6666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5156162478, createdName=ms3000000333745611, createdTime=Fri Dec 03 18:32:05 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966533, encodeId=c697966533b1, content=先评论再获取,不留空不留白, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75bd5503572, createdName=ms9000001418724535, createdTime=Tue May 18 11:52:24 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075043, encodeId=fe3f10e50438b, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb965634387, createdName=ms8000001030180834, createdTime=Mon Nov 29 12:29:46 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075042, encodeId=76ac10e50420f, content=666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb965634387, createdName=ms8000001030180834, createdTime=Mon Nov 29 12:29:35 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
    2021-11-29 ms8000001030180834

    666

    0

拓展阅读

乳腺癌HER2检测指南(2009版)

中国肿瘤科相关专家小组(统称) · 2009-12-01

2010 乳腺癌骨转移和骨相关疾病临床诊疗专家共识(2010版)

乳腺癌骨转移和骨相关疾病临床诊疗专家组 · 2010-01-01

2010 SBI/ACR推荐建议:乳腺癌影像学筛查

乳腺影像学会(SBI,Society of Breast Imaging) · 2010-01-20

2010 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识

中国抗癌协会乳腺癌专业委员会(CACA-CBCS,Chinese Anti-Cancer Association, Committee of Breast Cancer Society) · 2010-02-01

2010 ASCO-CAP指南:乳腺癌患者雌激素和雄激素受体的免疫组化检测

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-04-19

2010 ASCO指南:激素受体阳性乳腺癌妇女的辅助内分泌治疗

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-07-12